Preclinical Programs

About Immuneering

Immuneering is developing a new class of cancer medicines called Deep Cyclic Inhibitors, which employ a pulsed dosing strategy to overcome the limitations of traditional continuous inhibition. The company's lead programs target the MAPK pathway, a critical driver in many cancers, with the goal of delivering more durable responses and better tolerability. Immuneering is a publicly traded company (NASDAQ: IMRX) with a seasoned leadership team and a clear focus on transforming cancer care through innovative treatment paradigms.

About GenSight Biologics

GenSight Biologics is a Paris-based gene therapy company founded in 2012, focused on developing and commercializing novel therapies for retinal degenerative diseases and central nervous system disorders. Its core technology platforms combine gene therapy with a proprietary Mitochondrial Targeting Sequence (MTS) and optogenetics. The company has two product candidates in clinical trials, has received prestigious scientific recognition, and is preparing for the potential commercialization of its lead asset for LHON.

Therapeutic Areas